Obesity is associated with endothelial dysfunction related to decreased NO bioavailability, increased endothelin 1 vasoconstrictor activity, and decreased circulating ghrelin. Therefore, we tested whether exogenous ghrelin may have benefits to improve the balance between endothelin 1 and NO in patients with obesity-related metabolic syndrome. Vasoactive actions of endothelin 1 and NO were assessed in 8 patients with metabolic syndrome and 8 matched controls by evaluating forearm blood flow responses (strain-gauge plethysmography) to intra-arterial infusion of BQ-123 (endothelin A receptor antagonist; 10 nmol/min), followed by NG-monomethyl-L-arginine (NO synthase inhibitor; 4 micromol/min), before and after infusion of ghrelin (200 ng/min). In the absence of ghrelin, the vasodilator response to BQ-123 was greater in patients than in controls (P<0.001), whereas infusion of NG-monomethyl-L-arginine induced smaller vasoconstriction in patients than in controls (P=0.006). Importantly, exogenous ghrelin decreased the vasodilator response to BQ-123 (P=0.007 versus saline) and enhanced the magnitude of changes in forearm blood flow induced by NG-monomethyl-L-arginine (P=0.003) in patients but not in controls (both P>0.05). The favorable effect of ghrelin on endothelin A-dependent vasoconstriction was likely related to the stimulation of NO production, because no change in the vascular effect of BQ-123 was observed after ghrelin (P=0.44) in 5 patients with metabolic syndrome during continuous infusion of the NO donor sodium nitroprusside (0.2 microg/min). In patients with metabolic syndrome, ghrelin has benefits to normalize the balance between vasoconstrictor (endothelin 1) and vasodilating (NO) mediators, thus suggesting that this peptide has important peripheral actions to preserve vascular homeostasis in humans.

Tesauro, M., Schinzari, F., Rovella, V., DI DANIELE, N., Lauro, D., Mores, N., et al. (2009). Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. HYPERTENSION, 54(5), 995-1000 [10.1161/HYPERTENSIONAHA.109.137729].

Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome

TESAURO, MANFREDI;ROVELLA, VALENTINA;DI DANIELE, NICOLA;LAURO, DAVIDE;
2009-11-01

Abstract

Obesity is associated with endothelial dysfunction related to decreased NO bioavailability, increased endothelin 1 vasoconstrictor activity, and decreased circulating ghrelin. Therefore, we tested whether exogenous ghrelin may have benefits to improve the balance between endothelin 1 and NO in patients with obesity-related metabolic syndrome. Vasoactive actions of endothelin 1 and NO were assessed in 8 patients with metabolic syndrome and 8 matched controls by evaluating forearm blood flow responses (strain-gauge plethysmography) to intra-arterial infusion of BQ-123 (endothelin A receptor antagonist; 10 nmol/min), followed by NG-monomethyl-L-arginine (NO synthase inhibitor; 4 micromol/min), before and after infusion of ghrelin (200 ng/min). In the absence of ghrelin, the vasodilator response to BQ-123 was greater in patients than in controls (P<0.001), whereas infusion of NG-monomethyl-L-arginine induced smaller vasoconstriction in patients than in controls (P=0.006). Importantly, exogenous ghrelin decreased the vasodilator response to BQ-123 (P=0.007 versus saline) and enhanced the magnitude of changes in forearm blood flow induced by NG-monomethyl-L-arginine (P=0.003) in patients but not in controls (both P>0.05). The favorable effect of ghrelin on endothelin A-dependent vasoconstriction was likely related to the stimulation of NO production, because no change in the vascular effect of BQ-123 was observed after ghrelin (P=0.44) in 5 patients with metabolic syndrome during continuous infusion of the NO donor sodium nitroprusside (0.2 microg/min). In patients with metabolic syndrome, ghrelin has benefits to normalize the balance between vasoconstrictor (endothelin 1) and vasodilating (NO) mediators, thus suggesting that this peptide has important peripheral actions to preserve vascular homeostasis in humans.
nov-2009
Pubblicato
Rilevanza nazionale
Articolo
Sì, ma tipo non specificato
Settore MED/09 - MEDICINA INTERNA
Settore MED/13 - ENDOCRINOLOGIA
Settore MED/50 - SCIENZE TECNICHE MEDICHE APPLICATE
Settore MED/49 - SCIENZE TECNICHE DIETETICHE APPLICATE
English
Con Impact Factor ISI
Probability; Obesity; Reference Values; Analysis of Variance; Metabolic Syndrome X; Blood Flow Velocity; Humans; Vasoconstriction; Homeostasis; Endothelium, Vascular; Ghrelin; Nitric Oxide Synthase; Vasodilation; Adult; Case-Control Studies; Middle Aged; Plethysmography; Receptor, Endothelin A; Female; Forearm; Male
Tesauro, M., Schinzari, F., Rovella, V., DI DANIELE, N., Lauro, D., Mores, N., et al. (2009). Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. HYPERTENSION, 54(5), 995-1000 [10.1161/HYPERTENSIONAHA.109.137729].
Tesauro, M; Schinzari, F; Rovella, V; DI DANIELE, N; Lauro, D; Mores, N; Veneziani, A; Cardillo, C
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/41945
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 83
  • ???jsp.display-item.citation.isi??? 73
social impact